About the deal
FRAmelco Group, a family-owned multinational group headquartered in The Netherlands, operates 3 plants located in The Netherlands, Spain, and Thailand. Most of FRAmelco sales are made of Glycerides (short and medium chain fatty acids) to maintain animal in good health and to improve animal performance and Lysolecithins to improve feed digestibility. FRAmelco’s industrial footprint, its product range, its technologies, the species addressed, and its target markets are highly complementary to Adisseo’s. It will allow the combined business to implement integrated solutions and offer even more value to customers who want to reduce antibiotic usage and enhance animal resilience.
Adisseo is one of the world’s leading experts in feed additives. The group relies on its 10 research centers and its production sites based in Europe, USA, and China to design, produce and market nutritional solutions for sustainable animal feed. With more than 2,250 employees, it serves around 3,900 customers in over 110 different countries through its global distribution network. In 2019, Adisseo achieved a turnover of over 1.44 billion Euros.
Adisseo is one of the main subsidiaries of China National BlueStar, leader in the Chinese chemical industry with nearly 21,000 employees and a turnover of 6,8 billion USD; the company is listed on the Shanghai Stock Exchange.
What we did
Capitalmind actively supported FRAmelco as exclusive advisor along the entire sell-side process: marketing materials preparation, screening and selection of the relevant strategic and financial buyers through a competitive process, management of the due diligence and negotiation of terms and conditions of the deal plus ultimate closing of the transactions.